

Oxford Genome Sciences Appoints Professor Elke Jaeger to its Scientific Advisory Board

Oxford, UK, 18th February 2008. Oxford Genome Sciences (UK) Ltd “OGeS” announces that it has appointed Professor Elke Jaeger to the company’s Scientific and Clinical Advisory Board (SAB). Professor Jaeger is one of the world’s leading cancer immunologists, with significant experience in therapeutic antibodies and cancer vaccines, and she has run many single-center phase I clinical trials at the Ludwig Institute Clinical Trial Center.

Professor Jaeger has been the chief physician of the Medical Clinic II, haematology-oncology, Hospital Northwest Frankfurt, an academic teaching hospital of the Johann Wolfgang Goethe University, Frankfurt since April 2003. She is also director of the Ludwig Institute Clinical Trial Center, Frankfurt. In 1997 Professor Jaeger did her habilitation in internal medicine which was focused on immune responses against melanoma-associated antigens: foundations for the development of an antigen specific immunotherapy. Since 1992 she has managed a variety of Phase I / II / III clinical studies of potential drug treatments for various malignant diseases as well as a series of clinical and experimental studies on antigen specific T-cell immunology in patients with haematological and oncological diseases. Professor Jaeger is also a permanent member of the Ethics Commission of the National Medical Association Rheinland Pfalz, Germany and a member of the ‘Protocol Review Committee’ of the EORTC (European Organisation for Research and Treatment of Cancer) where she acts as a referee for study protocols.

Dr Christian Rohlff, CEO of OGeS, commented: “I am delighted that Professor Jaeger, one of the world’s leading cancer immunologists, has agreed to join our SAB. Access to her immense experience in the clinical development of novel cancer therapies will be of great value to OGeS as we embark on the development of our own portfolio of antibody products targeting various cancer indications.”

Professor Elke Jaeger, commenting on her appointment said, “I am very happy to be joining OGeS’ SAB. The company has taken an impressive approach to develop its own portfolio of antibodies for the treatment of cancer. Capitalising on its unique OGAP[®] discovery platform, in alliances with the world’s leading antibody companies, gives OGeS’ great potential to generate products to address significant unmet clinical needs and deliver important benefits to patients with this devastating disease.”

-Ends-

About Oxford Genome Sciences

Oxford Genome Sciences (OGeS) is focused on the development of targeted medicines for oncology. The company uses OGAP[®], which it has developed into the world’s largest cancer protein database, to discover novel clinically relevant drug targets and diagnostics.

OGeS’ strategy is to use its unique and integrated OGAP[®] discovery platform in alliances with the world’s leading antibody companies to develop OGeS targets into new antibody therapeutics and diagnostics that will deliver innovative and cost-effective medicines to fulfil unmet patient needs in the field of cancer. The company has signed a number of collaborations in the area of cancer, which are together designed to achieve OGeS’ objective of developing novel personalised solutions to the management of cancer. In late 2007 OGeS entered into an agreement with Amgen to discover, develop and commercialise novel therapeutic antibodies for the treatment of cancer. This deal with Amgen follows OGeS entering into partnerships with Medarex to discover, develop and commercialise new human

antibody therapeutics for the treatment of cancers and with Biosite to develop a new diagnostic protein panel for relapsing colorectal cancer in 2006.

OGeS, a privately held company, was formed in 2004 and is based near Oxford, UK.

About OGAP®

Oxford Genome Anatomy Project (OGAP) holds the world's largest proprietary collection of proteins represented by a database. It integrates genomic, proteomic and clinical information derived from blood and tissue studies for a large number of diseases from 50 different human tissues representing 60 diseases and contains over one million peptide sequences, mapped to approximately 15,000 genes and over eight million SNPs and haplotypes. OGAP oncology contains proteomic data on 5,000 cancer membrane proteins combined with their genomic and clinical information derived from human blood and cancer tissue studies.

OGAP® is a registered trade mark of Oxford Genome Sciences (UK) Ltd.

For further information, please see www.oxfordgenomesciences.com

For further information, please contact:

Oxford Genome Sciences

Dr Christian Rohlf, Chief Executive Officer
Tel: +44 (0)1235 861770
christian.rohlf@oxfordgenomesciences.com

Citigate Dewe Rogerson

David Dible, Amber Bielecka
Tel: +44 (0)207 638 9571
david.dible@citigatedr.co.uk